The Pagoclone Phase IIb study has still not been published. Several sources tell me that the company TEVA has all the data for several weeks now. There is no doubt in my mind that they know the outcome of the study. Sometimes they wait with an announcement to coincide with another corporate event. But the longer we have to wait, the more pessimistic I get. Do they actually have to publish the study? What if the study turns out to be a null-result, do they have to publish the details? I believe that they have to register their study, but I am sure how much of the data they have to release. It's very important that all studies are made public. If only the positive ones are published but the null ones not, we have a publication bias. And that can be a big big issue.